IPF

Respiratory

Prevalence

5.0 / 100K

20 drugs in development·16 companies·4 clinical trials

Drug Pipeline by Phase

Approved(8)

Drug	Company
etorel	GYRE THERAPEUTICS, INC. (GYRE)
nintedanib	X4 Pharmaceuticals, Inc (XFOR)
nintedanib	GYRE THERAPEUTICS, INC. (GYRE)
nintedanib	EXELIXIS, INC. (EXEL)
nintedanib	Aptinyx Inc. (APTX)
nintedanib	DR REDDYS LABORATORIES LTD (RDY)
nintedanib	NYMOX PHARMACEUTICAL CORP (NYMXF)
pirfenidone	Amneal Pharmaceuticals, Inc. (AMRX)

Phase 3(3)

Phase 2(2)

Drug	Company
gri-0621	GRI Bio, Inc. (GRI)
lti-03	Rein Therapeutics, Inc. (RNTX)

Phase 1(3)

Drug	Company
ANPA-0073	Structure Therapeutics Inc. (GPCR)
deupirfenidone	PureTech Health plc (PRTC)
mnkd-201	MANNKIND CORP (MNKD)

Preclinical(4)

Drug	Company
cb5138-3	COHBAR, INC. (COBU)
chit1 small molecule	Ocean Biomedical, Inc. (OCEA)
LTSE-2578	Structure Therapeutics Inc. (GPCR)
REC-4209	RECURSION PHARMACEUTICALS, INC. (RXRX)

BioSniper tracks 20 drugs in development for IPF across 16 companies.

There are 4 clinical trials targeting IPF tracked by BioSniper.

The estimated prevalence of IPF is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.